Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm

Size: px
Start display at page:

Download "Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm"

Transcription

1 Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm Department of Cardiology Keiji Inoue Akira Ueoka, Naoki Maruyama, Yoshiaki Shimoda, Eigo Kishita, Yoshinori Tsubakimoto, Tomohiko Sakatani, Akiko Matsuo, Hiroshi Fujita, Makoto Kitamura

2 Background 1 1. Coronary spasm has been shown to play an important role in the pathogenesis of not only vasospastic angina but also ischemic heart disease including angina pectoris, myocardial infarction and sudden death. 2. Despite a large number of experimental and clinical investigations, the precise pathophysiology and mechanisms of vasospasm remains unknown.

3 Background 2 1. Patients with coronary spasm may have endothelial cell dysfunction lead by oxidative stress. 2. Impaired reactivity of vascular smooth muscle has been reported as a chief mechanism of vasospasm. 3. Chronic low-grade inflammation seems to be associated with the pathogenesis of coronary spasm. 4. The renin-angiotensin-aldosterone system (RAAS) may cause both endothelial dysfunction and hypercontraction of coronary smooth muscle cell. 5. The aldosterone has the potential to increase vascular inflammatory reaction.

4 Circulation. 23;18:

5 Circulation. 27;116:

6 Control Aldosterone Kidney International. 25;67:

7 Am J Physiol Heart Circ Physiol. 22;283:

8 Hypothesis The elevated aldostrone, final mediator of RAAS, is supposed to induce vascular inflammatory injury followed by vasospasm. Aim We elucidated the role of the aldosterone and inflammation in coronary vasospasm patients.

9 Methods 1 1. Consecutive 48 patients without organic coronary lesion (213 men, 195 women, age 67.4±12.6) were studied. 2. After diagnostic coronary angiography spasm provocation test was performed using ergonovine maleate. 3. Patients with proven coronary vasospasm (> 9% vessel diameter reduction during selective intracoronary ergonovine maleate as compared with the diameter following intracoronary nitroglycerin) but without coronary stenosis were diagnosed as vasospasm angina. 4. Patients without vasospasm and organic coronary lesion were diagnosed as non-spasm disease.

10 Methods 2 1. According to the results of the provocation test, the subjects were divided into two groups: the Spasm group of 144 patients and the Non-spasm group of 264 patients. 2. The levels of aldosterone and C-reactive protein (CRP) measured immediately before angiography were examined. Clinical data including aldosterone and CRP and other coronary risk factors were compared between 2 groups. 3. Exclusion criteria acute coronary syndrome, end stage renal failure systemic inflammatory disease, malignant disease, aldosterone antagonist user

11 Results Non-Spasm Spasm P-value Number Age y.o. 67.1± ± Gender M/F 116/148 97/47 <.1 Height cm 159.2± ± Weight kg 58.6± ± BMI kg/m2 23.± ± Hypertension % Diabetes % Dyslipidemia % Hyperuremia % Smoker % Brinkman index 233.5± ±736.9 <.1

12 Results Non-Spasm Spasm P-value SBP mmhg 131.5± ± DBP mmhg 75.9± ± PP mmhg 55.3± ± HR /min 72.4± ± EF % 75.2± ±11.2 <.1

13 Results Non-Spasm Spasm P-value BNP pg/ml 34.7± ± <.1 Aldosterone pg/ml 19.5± ±68.9 <.1 Renin activity ng/ml/hr 3.3± ± WBC /mm ± ± Neutrophil /mm ± ± Lymphocyte /mm ± ± Fibrinogen mg/dl 292.7± ± CRP mg/l.93± ±.95 <.1

14 Results Non-Spasm Spasm P-value Total-cholesterol mg/dl 199.7± ± Trigriceride mg/dl 139.3± ± HDL-cholesterol mg/dl 54.6± ± Uric Acid mg/dl 5.5± ± Blood sugar mg/dl 111.4± ± HbA1c % 5.5±.9 5.6± BUN mg/dl 16.2± ± Creatinine mg/dl.8±.23.93± egfr ml/min/1.73m ± ± Na meq/l 14.4± ± K meq/l 4.2±.4 4.2± Cl meq/l 12.1± ±

15 %male 1 8 Gender BMI Smoking P =.12 kg/m (Brinkman index ) n.s. P = Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

16 BNP Aldosterone Renin pg/ml 16 pg/ml 8 ng/ml/hr 1 P =.17 P <.1 n.s Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

17 CRP Neutrophil Fibrinogen mg/l 1. /mm 3 16 mg/dl 1 P <.1 14 P <.1 8 n.s Non-spasm Spasm Non-spasm Spasm Non-spasm Spasm

18 Non-spasm Spasm CRP (mg/l) 1. n = 264 CRP (mg/l) 1. n = R =.4 P = R =.79 P < Plasma Aldosterone (pg/ml) Plasma Aldosterone (pg/ml) y =.2x ; R 2 =.1525 y =.97x +.544; R2=.524

19 Spasm Neutrophil (/mm 3 ) 1 8 Fibrinogen (mg/dl) n = 12 1 n = 12 R =.391 R =.426 P <.1 8 P < Plasma Aldosterone (pg/ml) Plasma Aldosterone (pg/ml) y = x ; R 2 = y =.3546x ; R =.1812

20 Multivariate Analysis Odds ratio (95% CI) P-value Aldosterone 1.6 ( ).19 CRP ( ).198 Neutrophil 1. ( ).653 Smoker 1.75 ( ).529

21 Summary 1. Levels of aldosterone and CRP were significantly higher in the spasm group than in the non-spasm group 2. Patients with coronary vasospasm were likely to have high levels of white blood cell count and neutrophil count. 3. There is a positive correlation between aldosternoe and CRP in the spasm group. 4. Multivariate analysis showed that elevation of aldosterone and CRP level were independently associated with vasospasm.

22 RAA system Aldosterone Aldosterone Receptors in Vessels Non-RAA system Adipocyte ACTH Potassium Endothelin Deleterious Effects of Aldosterone in Artery Coronary spasm? Endothelial Dysfunction VSMC Hypercontraction Oxidative Stress Inflammatory Reaction Thrombotic Phenomena Vascular Fibrosis

23 Pathogenesis of vasospasm 1. Shear stress, Acetylcholine, Bradykinin, Serotonin, Histamine, Substance P 2. Endothelial dysfunction Endothlium-dependent vaso-relaxation factors =EDRF (NO), EDHF Endothlium-derived contracting factors (EDCF) =ET-1, Angiotensin II, PGH2, TXA2, Super oxide 3. Oxidative stress Aldosterone NADPH oxidase activation 4. Chronic low-grade vascular inflammation 5. Hyper contractility of vascular smooth muscle cell Rho/ROCK activity 6. Deficiency of magnesium (endgenous Ca antagonist) 7. Loss of estrogen

24 Limitations 1. Cause of elevated aldosterone 2. Role of cortisol 3. Expression of mineral corticoid receptor 4. Effect of mineral corticoid receptor blocker 5. Racial differences, Ethnic characteristics

25 Conclusions 1. The levels of aldosternoe and CRP which were strongly associated with vasospasm had positive interactions. 2. Our results suggested elevated aldosterone in conjunction with inflammatory reaction may be involved in the pathogenesis of coronary spasm.

Cho et al., 2009 Journal of Cardiology (2009), 54:

Cho et al., 2009 Journal of Cardiology (2009), 54: Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice

Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice Research article Interventional Cardiology Acetylcholine coronary spasm provocation testing: Revaluation in the real clinical practice Background: Japanese Circulation Society guidelines for coronary spastic

More information

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Tables of Normal Values (As of February 2005)

Tables of Normal Values (As of February 2005) Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Aspirin Resistance in Patients with Chronic Renal Failure (P 5325)

Aspirin Resistance in Patients with Chronic Renal Failure (P 5325) Aspirin Resistance in Patients with Chronic Renal Failure (P 5325) Beste Ozben Sadic 1, Azra Tanrikulu 1, Mehmet Koc 2, Tomris Ozben 3, Oguz Caymaz 1 1 Marmara University, Faculty of Medicine, Department

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

AGING KIDNEY IN HIV DISEASE

AGING KIDNEY IN HIV DISEASE AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV

More information

A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY

A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY Case 57 y.o. male CC: Weakness HPI: About 20 years ago, he developed bilateral lower extremity weakness. Laboratory

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association between arterial stiffness and cardiovascular risk factors in a pediatric population + Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro

More information

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±

More information

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Serotonin Receptor Blockade Effective for Postprandial Vasospastic Angina Associated With Dumping Syndrome After Esophagectomy:

Serotonin Receptor Blockade Effective for Postprandial Vasospastic Angina Associated With Dumping Syndrome After Esophagectomy: 1 Serotonin Receptor Blockade Effective for Postprandial Vasospastic Angina Associated With Dumping Syndrome After Esophagectomy: A Case Report Takamasa Takanori Norifumi Mikihisa Masatoshi Masanobu Muneyasu

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

Patient is healthy with no chronic disease or significant risk factors [16%].

Patient is healthy with no chronic disease or significant risk factors [16%]. AAFP Risk Level 1 Patient is healthy with no chronic disease or significant risk factors [16%]. Exclude the following chronic problems from active patient list o Depression o Diabetes Type I or Type II

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST

UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST Please check the requested variables:, and/or. Obtained at Initial Hospital Recruitment Demographics: Age Gender Marital Status Ethnicity Race Height (inches) Weight (pounds) Main language spoken Socioeconomic

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA

More information

Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy

Classification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Aldosterone Antagonism in Heart Failure: Now for all Patients? Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C

More information

HFpEF, Mito or Realidad?

HFpEF, Mito or Realidad? HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY

More information

Cardiovascular disease and diabetes Vascular harmony

Cardiovascular disease and diabetes Vascular harmony Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics

More information

http://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current

More information

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti

More information

300 Biomed Environ Sci, 2018; 31(4):

300 Biomed Environ Sci, 2018; 31(4): 300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of

More information

ijcrr A DIFFUSE CORONARY SPASM A VARIANT OF A VARIANT?

ijcrr A DIFFUSE CORONARY SPASM A VARIANT OF A VARIANT? A DIFFUSE CORONARY SPASM A VARIANT OF A VARIANT? A.Noel, B. Amirthaganesh ijcrr Vol 04 issue 01 Category: Case Report Received on:19/10/11 Revised on:24/10/11 Accepted on:28/10/11 Department of Cardiology,

More information

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Narbeh Melikian*, Ajay M Shah*, Martyn R Thomas, Roy Sherwood, Mark T

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,

More information

Aldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow

Aldosterone synthase inhibitors. John McMurray BHF Cardiovascular Research Centre University of Glasgow Aldosterone synthase inhibitors John McMurray BHF Cardiovascular Research Centre University of Glasgow Inhibition of aldosterone synthesis is hypothesized to be of benefit to patients with cardiovascular

More information

coronary spasm (CS). Interactions between hemoglobin and high-sensitivity C-reactive protein (hs-crp) in patients with CS have not been

coronary spasm (CS). Interactions between hemoglobin and high-sensitivity C-reactive protein (hs-crp) in patients with CS have not been 1 2 Background The benefit of modest anemia, although well known in cerebral spasm, is unclear in coronary spasm (CS). Interactions between hemoglobin and high-sensitivity C-reactive protein (hs-crp) in

More information

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery

Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry

More information

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys

More information

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure. Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico

More information

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori

More information

IN-HF on line: patient settings (Enrollement period= )

IN-HF on line: patient settings (Enrollement period= ) IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee

More information

Hypertension Management in Diabetic Patients

Hypertension Management in Diabetic Patients Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension

More information

REGULATION OF CARDIOVASCULAR SYSTEM

REGULATION OF CARDIOVASCULAR SYSTEM REGULATION OF CARDIOVASCULAR SYSTEM Jonas Addae Medical Sciences, UWI REGULATION OF CARDIOVASCULAR SYSTEM Intrinsic Coupling of cardiac and vascular functions - Autoregulation of vessel diameter Extrinsic

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Content Introduction The number 1 killer in America Some statistics

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Structure and organization of blood vessels

Structure and organization of blood vessels The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins

More information

Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris

Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris Circ J 2006; 70: 414 418 Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris Soon Jun Hong, MD; Hong Seog Seo, MD; Seung Woon Rha, MD; Dong Joo Oh, MD; Jung Ah Kwon,

More information

Real World Experience with Renal Denervation Therapy

Real World Experience with Renal Denervation Therapy JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

The Study of Endothelial Function in CKD and ESRD

The Study of Endothelial Function in CKD and ESRD The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Supplementary Note Details of the patient populations studied Strengths and weakness of the study

Supplementary Note Details of the patient populations studied Strengths and weakness of the study Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined

More information

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS Daisuke MAEBUCHI, Yasuyuki SHIRAISHI, Hiroaki TANAKA, Yumiko INUI, Makoto TAKEI,

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Review Article Coronary Arteries and Coronary Vasospasm: The Anatomical and Molecular Aspects Ashfaqul Hassan 1*, Ghulam

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to 90 mmhg. These pressures are called Normal blood pressure

More information

The Impact of Smoking on Acute Ischemic Stroke

The Impact of Smoking on Acute Ischemic Stroke Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

HYPERTENSIVE VASCULAR DISEASE

HYPERTENSIVE VASCULAR DISEASE HYPERTENSIVE VASCULAR DISEASE Cutoffs in diagnosing hypertension in clinical practice sustained diastolic pressures >90 mm Hg, or sustained systolic pressures >140 mm Hg Malignant hypertension A small

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL Douglas G. Kelling Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised, April 8, 2012 The information contained in this protocol

More information

Cardiorenal Syndrome

Cardiorenal Syndrome SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal

More information

The Author(s) This article is published with open access by ASEAN Federation of Cardiology

The Author(s) This article is published with open access by ASEAN Federation of Cardiology DOI 10.7603/s40602-014-0011-3 ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 60 65 (2014) ISSN: 2315-4551 Erratum Erratum to: Impact Of Sex On Clinical Characteristics And In-Hospital

More information

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Cardiovascular Pharmacotherapy

Cardiovascular Pharmacotherapy Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

Low HDL-levels: leave it or treat it?

Low HDL-levels: leave it or treat it? Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

More information

Importance of the Spasm Provocation Test in Diagnosing and Clarifying the Activity of Vasospastic Angina

Importance of the Spasm Provocation Test in Diagnosing and Clarifying the Activity of Vasospastic Angina Research Article imedpub Journals www.imedpub.com Interventional Cardiology Journal ISSN 2471-8157 DOI: 10.21767/2471-8157.100058 Abstract Importance of the Spasm Provocation Test in Diagnosing and Clarifying

More information

SMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR

SMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging

More information

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Condition/Procedure Measure Compliance Criteria Reference Attribution Method Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is

More information

Ischemic heart disease

Ischemic heart disease Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Investigating the Frequency of Atherosclerosis Risk Factors in Patients Suffering from X Syndrome

Investigating the Frequency of Atherosclerosis Risk Factors in Patients Suffering from X Syndrome Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2016, 5, 10:84-90 Investigating the Frequency of Atherosclerosis Risk Factors in Patients

More information

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Assessment of vitamin D levels in patients with acute coronary syndrome

Assessment of vitamin D levels in patients with acute coronary syndrome ORIGINAL ARTICLE East J Med 21(4): 178-182, 2016 Assessment of vitamin D levels in patients with acute coronary syndrome Hakki Simsek and Naci Babat * Yuzuncu Yil University, Faculty of Medicine, Cardiology

More information

Antialdosterone treatment in heart failure

Antialdosterone treatment in heart failure Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition

More information

M2 TEACHING UNDERSTANDING PHARMACOLOGY

M2 TEACHING UNDERSTANDING PHARMACOLOGY M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To

More information

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR

More information